Table 1.
Clinical characteristics of patients in our cohort (n = 82)
| Characteristic | No. of patients (%) |
|---|---|
| Mean age (standard deviation) | 57 years (14) |
| Male sex | 54 (66) |
| Race/ethnicity | |
| White | 63 (77) |
| Black | 7 (9) |
| Hispanic | 9 (11) |
| Other | 3 (4) |
| Baseline risk factors | |
| History of smoking | 35 (43) |
| Alcohol consumption | 35 (43) |
| Type II diabetes mellitus | 21 (26) |
| Drug allergy | 51 (62) |
| Prior history of pancreatitis | 7 (9) |
| Pancreatic metastasis | 11 (13) |
| Cancer type | |
| Melanoma | 30 (37) |
| Genitourinary | 24 (29) |
| Lung, head and neck | 11 (13) |
| Gastrointestinal | 5 (6) |
| Other solid tumors | 5 (6) |
| Hematologic malignancies | 7 (9) |
| Cancer stagea | |
| Stage III | 3 (4) |
| Stage IV | 72 (96) |
| Median number of immune checkpoint inhibitor doses (interquartile range) | 4 (1-25) |
| Checkpoint inhibitor type | |
| CTLA-4 monotherapy | 12 (15) |
| PD-1/L1 monotherapy | 53 (65) |
| Combination therapyb | 17 (21) |
| Other immune-related adverse events | |
| Gastrointestinal | 27 (33) |
| Hepatic | 17 (21) |
| Dermatologic | 13 (16) |
| Endocrine | 7 (9) |
| Pulmonary | 5 (6) |
| Other | 6 (7) |
aCancer stage was recorded for 75 patients. For solid tumors, the TNM system of the American Joint Committee on Cancer 7th edition was used for cancer staging. No cancer stage was record for hematologic cancer
bCombination of CTLA-4 and PD-1 or PD-L1 therapy